The following is a summary of “Association between different proportions of crescents and the progression of IgA nephropathy ...

BioCity Biopharma has reported positive Phase II results for SC0062 in treating IgA nephropathy, showing up to a 48.3% ...

Dealmaking this year has been largely muted, but M&A trends are pointing to the areas where pharma is placing the most ...

程虹教授：目前，肾科医生对SGLT2抑制剂的肾脏保护作用已经有越来越深的认识，在临床实践中，SGLT2抑制剂可能更多用于非糖尿病的CKD患者，且发挥了非常重要的作用，包括降低蛋白尿、延缓肾病进展。实际上，当RAS抑制剂和SGLT2抑制剂联用时，患者蛋白尿可显著下降 5 。此外，有些患者可能由于血压较低，使用RAS抑制剂会受限，临床可能会选择SGLT2抑制剂来降低蛋白尿，同样也观察到非常好的临床疗效 ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

The company’s recent financial position is robust, with substantial cash reserves and proceeds from a public offering expected to sustain operations through the potential approval and commercial ...

Q3 2024 Earnings Call Transcript October 31, 2024 Travere Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...

Good day and welcome to the Vertex Pharmaceuticals third-quarter 2024 earnings call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to ...

Q3 2024 Earnings Call Transcript November 4, 2024 Vertex Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.38, expectations were $4.14. Operator: Good day. And welcome to ...

Jade Biosciences, Inc., a privately held biotechnology company dedicated to developing best-in-class therapies for patients ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...